KemPharm, Inc. Reports First Quarter 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
KemPharm (KMPH) Tops Q1 EPS by 26c
May 12, 2016 4:47 PM EDTKemPharm (NASDAQ: KMPH) reported Q1 EPS of ($0.20), $0.26 better than the analyst estimate of ($0.46).
This has been a significant period for KemPharm. Last weeks joint advisory committee meeting with the FDAs Anesthetic and Analgesic Drug Products and Drug Safety and Risk Management committees voted in support of approving Apadaz for the management of acute pain that requires an opioid, yet recommended against including abuse deterrent... More
